Navigation Links
Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials
Date:3/20/2008

Wows Rome audience with live study setup and launch...

WAYLAND, Mass., March 20 /PRNewswire/ -- Tourtellotte Solutions, a global leader in bio-pharmaceutical clinical trials software, announces the launch of its Trident IWR(TM) next-generation IWR/IVRS platform for phase II-IV studies. Trident's unique parameter driven + custom pluggable design leaps ahead of legacy IVRS technologies and promises to deliver a new era of needed scalability, productivity, and ease-of-use to the straining global clinical IVRS market.

Tourtellotte representatives demonstrated the next-generation Trident IWR, fully integrated with the tcVisualize(TM) clinical supply simulator, to an appreciative audience at the VIB Clinical Supply Europe conference in Rome, Italy on February 25th, 2008.

Clinical IVRS (or IWR) systems are the source and driver of patient randomization, drug dispensing, and trial supply logistics, and as such are critical to the multi-center clinical trials that they support. Having grown up from older telephony-based technology and designs, however, current IVRS platforms are difficult to scale, and time consuming to set up. Some estimates put the industry standard programming time for a new clinical trial in IVRS to be 8-12 weeks, with commensurate cost, risk and technical design and validation overhead.

A parameter driven IWR such as Trident can eliminate this lead-time and a host of other difficulties due to its parameterized design, coupled with automatic 2-way integration with trial simulators such as tcVisualize. The Tourtellotte team in Rome demonstrated this concept by soliciting a live study design from the audience, then setting up and simulating the study in tcVisualize, and exporting the study to Trident. After switching on the study in Trident IWR, the TS team then acted as a clinical site to screen, randomize, and dose subjects, and then brought the data back into tcVisualize to show end to end study design, launch, execution and review -- typically a 12 week process -- in less than 30 minutes.

"I believe that the time for next-generation IWR has come", said Ed Tourtellotte, president & CEO of Tourtellotte Solutions. "There is a lot of pressure on the IVRS market right now -- demand is growing faster than legacy technologies can scale to meet it. Service outages are in the press. Both vendors and bio-pharmaceuticals are starting to realize that a more modern, more scalable technology is badly needed."

In 2001, Tourtellotte Solutions pioneered the first major parameter-driven IVRS (and also the world's first IWR) for a global pharmaceutical company. The success of this model over time, coupled with pluggable customization modules and other Tourtellotte innovations, has proven the value and utility of next-generation IWR concepts. More recently, Tourtellotte Solutions has made waves with its groundbreaking and now market-leading tcVisualize clinical supply simulator, and is well positioned to deliver integrated next-generation IWR / IVRS technology to the bio-pharmaceutical industry in 2008.

For more information on Tourtellotte Solutions and the Trident IWR product, please visit http://www.TridentIWR.com. For information on the tcVisualize product, please visit http://www.tcVisualize.com.

About Tourtellotte Solutions

Tourtellotte Solutions is a global leader in software and services for the bio-pharmaceutical industry. In addition to Trident IWR, Tourtellotte Solutions' offers tcVisualize, a groundbreaking clinical supply chain modeling and forecasting used by many leading bio-pharmaceutical companies, and the Fusion DMC(TM) Document Management, Workflow and Collaboration Platform. Tourtellotte also provides custom application development and consulting services. Tourtellotte Solutions is a privately held company headquartered in Wayland, Massachusetts.

For more information on Tourtellotte Solutions or its products, please call Paul Colburn at 1.860.833.1710, or visit http://www.tourtellottesolutions.com.

Contact: Paul Colburn

Tourtellotte Solutions

860.833.1710

pcolburn@tci9.com


'/>"/>
SOURCE Tourtellotte Solutions
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Discovery Institute Bioethicist Lauds Breakthrough in Stem Cells Research that Eliminates Need for Human Cloning
2. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
3. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
4. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
5. Diamyd Gets Authorization to Begin Phase III Study in the US
6. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
7. Study Finds Broadband Access Key to Empowerment of Minority Communities
8. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
9. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
10. Fralex reaches 100th patient milestone in fibromyalgia study
11. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):